Impact of the COVID-19 pandemic on percutaneous coronary interventions in Portugal

INTRODUCTION

The COVID-19 pandemic has imposed an unprecedented burden on healthcare systems worldwide, changing the profile of interventional cardiology activity.

OBJECTIVES

To quantify and compare the number of percutaneous coronary interventions (PCIs) performed for acute and chronic coronary syndromes during the first COVID-19 outbreak with the corresponding period in previous years.

METHODS

Data on PCI from the prospective multicenter Portuguese Registry on Interventional Cardiology (RNCI) were used to analyze changes in PCI for ST-elevation myocardial infarction (STEMI), non-ST-elevation acute coronary syndromes (NSTE-ACS) and chronic coronary syndromes (CCS). The number of PCIs performed during the initial period of the COVID-19 outbreak in Portugal, from March 1 to May 2, 2020, was compared with the mean frequency of PCIs performed during the corresponding period in the previous three years (2017-2019).

RESULTS

The total number of PCIs procedures was significantly decreased during the initial COVID-19 outbreak in Portugal (-36%, p<0.001). The reduction in PCI procedures for STEMI, NSTE-ACS and CCS was, respectively, -25% (p<0.019), -20% (p<0.068) and -59% (p<0.001).

CONCLUSIONS

Compared with the corresponding period in the previous three years, the number of PCI procedures performed for STEMI and CCS decreased markedly during the first wave of the COVID-19 pandemic in Portugal.

Clinical Case 22—When the unusual appears

Clinical case

A 57 years old female, smoker, presented to emergency department with a constrictive chest and epigastric pain lasting for 30 minutes. Admission electrocardiogram showed a sinus bradycardia and ST elevation in the inferior leads. Inferior STEMI was assumed and was referred for primary coronary intervention. Coronary angiography revealed a right coronary artery (RCA) occluded at ostial level and primary angioplasty was performed with drug eluting stent implantation. After angioplasty, the chest pain didn´t relief, although the procedure had no complications. Transthoracic echocardiogram revealed a ‘flap’ on the ascending aorta (AAo), suggesting dissection of the AAo; left ventricular systolic function preserved, with hypokinesia of the inferior wall; right ventricular dysfunction; aortic regurgitation and no pericardial effusion. Emerging angio CT confirmed type A aortic dissection extending to abdominal aorta. The patient was then admitted to the operating room and a supracoronary conduit (hemiarch) and a bypass (saphenous vein/RCA) procedure was done. She had progressive clinical improvement and was discharged on the 17th day.

Learning points

Acute aortic dissection is the most common acute aortic syndrome (AAoS), being more prevalent in males and in the elderly, presenting high mortality rate. Acute type A aortic dissection can be difficult to diagnose and can mimic STEMI. RCA is more often involved when myocardial infarction is present. What appeared to be a linear STEMI turned out to be an AAoS that could have a catastrophic outcome. This was a successful case of this unusual diagnosis that surprised the entire team.

The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry

Aims 

The Acute Cardiac Care Association (ACCA)–European Association of Percutaneous Coronary Intervention (EAPCI) Registry on ST-elevation myocardial infarction (STEMI) of the EurObservational programme (EORP) of the European Society of Cardiology (ESC) registry aimed to determine the current state of the use of reperfusion therapy in ESC member and ESC affiliated countries and the adherence to ESC STEMI guidelines in patients with STEMI.

Methods and results 

Between 1 January 2015 and 31 March 2018, a total of 11 462 patients admitted with an initial diagnosis of STEMI according to the 2012 ESC STEMI guidelines were enrolled. Individual patient data were collected across 196 centres and 29 countries. Among the centres, there were 136 percutaneous coronary intervention centres and 91 with cardiac surgery on-site. The majority of centres (129/196) were part of a STEMI network. The main objective of this study was to describe the demographic, clinical, and angiographic characteristics of patients with STEMI. Other objectives include to assess management patterns and in particular the current use of reperfusion therapies and to evaluate how recommendations of most recent STEMI European guidelines regarding reperfusion therapies and adjunctive pharmacological and non-pharmacological treatments are adopted in clinical practice and how their application can impact on patients’ outcomes. Patients will be followed for 1 year after admission.

Conclusion 

The ESC ACCA-EAPCI EORP ACS STEMI registry is an international registry of care and outcomes of patients hospitalized with STEMI. It will provide insights into the contemporary patient profile, management patterns, and 1-year outcome of patients with STEMI.

RIVER: Portuguese registry to monitor unnecessary right ventricular pacing

The aim of this prospective registry is to evaluate a new algorithm designed to reduce the percentage of unnecessary ventricular pacing (%VP) in patients implanted with a dual-chamber pacemaker, through a dedicated pacing mode (called AAISafeR2) operating in AAI mode with back-up ventricular pacing in DDD mode, and to describe the incidence and distribution of atrioventricular (AV) block in this population. Investigators were free to assign patients to AAISafeR2 mode or to standard DDD (if AAISafeR was contraindicated, mainly due to permanent high-degree AV block). Patients underwent routine follow-up visits at 3, 6, 12, 18 and 24 months after implantation. At each follow-up visit, data were retrieved from pacemaker memories and analyzed to extract %VP and incidence of AV block. Up to December 2006, 158 patients (94 men, mean age 69 +/- 14 years) from nine Portuguese centers had been consecutively included. We also determined the distribution of AV block (according to the criteria used by the pacemaker to classify AV block and switch to DDD mode). AAISafeR was shown to be effective in reducing unnecessary VP in our patient population. The analysis also reveals a high incidence of paroxysmal AV block, often unknown at the time of implantation. There were no complications associated with AAISafeR programming.

Acute myocardial infarction after thrombolytic treatment of acute ischemic stroke

Thrombolytic treatment in patients with acute ischemic stroke improves their clinical prognosis when administered within three hours of symptom onset. We report the case of a 57-year-old patient with a history of paroxysmal atrial fibrillation and hypertension who developed an anterior acute myocardial infarction after systemic thrombolytic treatment for acute ischemic stroke. Embolization of a pre-existing cardiac thrombus or in situ formation of a thrombus in a coronary artery has to be considered as a potential adverse effect of thrombolytic therapy in stroke patients.

Clinical and angiographic profile of the diabetic patient: one-year follow-up

Diabetes mellitus is associated with significant cardiovascular morbidity and mortality. The authors describe the clinical and angiographic profile of a diabetic population undergoing percutaneous coronary intervention, with one-year follow-up.

METHODS

We retrospectively studied 769 patients (241 diabetic [D] and 528 nondiabetic [ND]) in terms of clinical and demographic characteristics, angiography and angioplasty data, and medical therapy, and analyzed the composite endpoint of adverse cardiac events at one month and one year.

RESULTS

Women, older mean age, hypertension, dyslipidemia, previous stroke and renal insufficiency were more prevalent in the D group. It also had more patients with left ventricular dysfunction, multivessel disease and complex coronary lesions. A significantly higher number of stents per patient and more drug-eluting stents were implanted in this group. Occurrence of the composite endpoint at one-year follow-up was significantly higher in diabetic patients (D = 23.6% vs. ND = 15.9%; p = 0.012), and one-year total mortality was 5.8% in the D group vs. 2.3% in the ND group (p = 0.012).

CONCLUSION

Even with aggressive percutaneous and pharmacological management, diabetes mellitus still has an adverse long-term prognosis.

Mortality and morbidity trends in ischemic heart disease in the autonomous region of Madeira in the ten-year period 1987-1996

The increase in absolute number of deaths from ischemic heart disease (IHD) in the population aged > or = 65 years, in both sexes, in Madeira, when comparing the years 1987 and 1996, led to significant increases in the corresponding standardized death rates that go against the stabilization seen at national level. Significant increases in these rates for the same years were also seen in the district of Beja and in the Azores. The aim of this study was to ascertain the trends for the incidence, morbidity and mortality from acute myocardial infarction (AMI) in patients admitted in Madeira and its contribution to the increase in these rates, particularly in the population aged < 65 years of both sexes, which the number of deaths from ischemic heart disease did not increase. We studied 119 pts with AMI admitted in 1987 (year A), of whom 53 were aged < 65 years, and 186 pts with AMI admitted in 1996 (year B), of whom 72 were aged < 65 years, whose data were included in the Madeira Ischemic Heart Disease Register (RECIMA), an IHD hospital register that covers 1792 patients admitted with AMI in the Coronary Intensive Care Unit of the Department of Medical and Surgical Cardiology of Funchal Hospital over a period of 15 years (1984-1998). Mortality by the 28th day (fatal AMI admissions) in all ages fell slightly in both sexes in the two years studied (A = 19.3%; B = 16.1%). The number of fatal AMI admissions rose among females in the two age groups considered A = 11; B = 20; delta% = +45) and fell among males (A = 12; B = 10; delta% = -20). In males aged > or = 65 years, this number remained the same (A = 7; B = 7) and fell in males aged > or = 65 years (A = 5; B = 3; delta% = -40). The number of pts who survived to the 28th day (non-fatal AMI admissions) rose in all age groups for both sexes (A = 96; B = 156; delta% = +38.46), as did the ratios with deaths from IHD. These increases were roughly double in the group of patients aged 65 years compared to patients aged < 65 years. We found highly significant positive correlations in the population aged < 65 years between the number of non-fatal AMI admissions (morbidity data) and the number of deaths from IHD (mortality data) recorded in every year of the 10-year period 1987-96, these values being highly significant in both sexes (r = 0.89; p < 0.0001), in males (r = 0.87; p < 0.0001) and in females (r = 0.77; p < 0.0001). Since our study was carried out on an island on which all AMI cases are admitted to a single treatment center, we can conclude that these positive correlations represent a trend towards worsening of morbidity and mortality from IHD in Madeira in the population aged < 65 years, even though the number of deaths from IHD did not rise. The establishment of IHD registers similar to RECIMA in other regions of the country would help to identify trends in morbidity, mortality, and morbidity plus mortality in this population that would be useful in improving the orientation of resources allocated to the prevention and treatment of cardiovascular diseases.

Survival analysis within one year of first acute myocardial infarction: comparison between non-Q and Q wave myocardial infarction

BACKGROUND

Non-Q wave Myocardial Infarction (non-Q AMI) is related pathophysiologically to Q wave AMI, as each represents different stages of plaque rupture and thrombosis. Post-hospital re-infarction and recurrent angina are more frequent in non-Q AMI than in Q wave AMI, offsetting the higher early risk with Q wave AMI, with one-year survival rates similar in the two types of MI.

OBJECTIVES

1--Evaluation of early (< or = 28 days) and one-year total mortality from first non-Q AMI in comparison to QMI. 2--Analysis of recurrent acute ischaemic events (non-fatal reinfarction and unstable angina) in both types of MI in the same periods of time.

POPULATION AND METHODS

A retrospective study of 1146 patients, mean age 65 +/- 13 years, 65% male, admitted at CCU with a first MI, from January 1988 to December 1997 (minimum follow-up period of one year, mean follow-up 42 +/- 37 months). We compared the baseline demographics and clinical characteristics (coronary risk factors, previous angina, MI evolution, recurrent cardiac events, 28 day mortality and one year mortality) of patients with non-Q AMI (NQ group = 239) and Q wave AMI (Q group = 907).

RESULTS

The NQ group patients were significantly older (mean age: 67 +/- 12.6 vs 65 +/- 12.5 years; p < 0.05), included fewer smokers (29% vs 43%; p < 0.001) and were more symptomatic before the index infarction (stable angina: 40% vs 30%; p < 0.05; unstable angina: 16% vs 6%; p < 0.001), when compared to the Q group patients. There were no significant differences in MI evolution, in Killip-Kimbal class > or = 2, recurrent angina and in-hospital mortality (Q-12% vs NQ-9%; ns), although there was a higher combined risk of arrhythmias and AV conduction disturbances in patients with QMI (Q-34% vs NQ-26%; p < 0.05). The combined risk of unstable angina and reinfarction at one year was significantly higher in group NQ (NQ-13% vs Q-8.1%; p < 0.05). The NQ group showed no significant difference in 28 day total mortality (NQ-14% vs Q-17%; ns) or at one year follow-up (NQ-24% vs Q-26%; ns) when compared to the Q group.

CONCLUSION

1--Despite a lower severity of non-Q AMI in the acute phase, 28 day and one year total mortality were similar in the two groups. 2--Patients with non-Q AMI showed a higher incidence of recurrent ischemic events at one year follow-up.

Thrombolytic therapy impact on prognosis after twelve months of first acute myocardial infarction

INTRODUCTION AND OBJECTIVES

Thrombolytic therapy is still widely used to restore antegrade flow in the infarct related artery (IRA), with unquestionable benefits in mortality reduction of such patients. The aim of this study was to evaluate early (< or = 28 days) and one-year mortality of patients with a first Q wave myocardial infarction (Q AMI), comparing those who underwent thrombolytic therapy with those who did not.

POPULATION AND METHODS

A retrospective study was done on 907 patients (median age: 35 +/- 13 years, 66% male) admitted to a Coronary Unit with the diagnosis of first Q AMI, from January 1988 to December 1997, all in the same geographical area (minimum follow-up period of one year, mean follow-up 43 +/- 37 months). We compared demographics and clinical characteristics (coronary risk factors, previous history of angina, MI location and evolution, cardiac events, 28 day and one-year mortality) of patients who underwent thrombolysis (group T = 355) versus those who did not undergo reperfusion therapy (group NT = 552).

RESULTS

Of these patients 39% underwent thrombolytic therapy. Group NT had a greater number of female patients (40% vs 25%; p < 0.001), a significantly higher mean age (67 +/- 12.2 vs 61 +/- 12; p < 0.001), and a higher percentage of diabetics (29% vs 19%; p < 0.001), in comparison to group T. The Q AMI developed into Killip class > or = 2 in 43% of patients in group NT and 23% in group T (p < 0.001). A higher number of AV block (NT-13% vs T-8%; p < 0.05) and higher in-hospital mortality (NT-14% vs T-9%; p < 0.05) was observed in patients not undergoing thrombolysis. The early (NT-22% vs T-12%; p < 0.001) and one-year (NT-33% vs T-16%; p < 0.001) mortalities were significantly higher in group NT than in group T, even after multivariate analysis.

CONCLUSIONS

1--Patients who did not undergo thrombolytic therapy initially had a profile of greater severity, and a higher early and one-year mortality rate. 2--Those who underwent thrombolytic therapy presented a significantly lower mortality, a benefit that was still observed after one year of follow-up and after multivariate correction.

[Value of exercise test for risk stratification acute myocardial infarction]

OBJECTIVES

To assess the prognostic value of predischarge exercise testing (ET) in patients hospitalized for acute myocardial infarction (AMI).

CONTEXT

Department of Cardiology in a reference hospital for Interventional Cardiology

METHODS

Between January 1990 and December 1994, 178 patients hospitalized for AMI were discharged and referred to the outpatient clinic (mean follow up, 1049 +/- 612 days). Eighty-two percent of these patients were men, mean age--56 +/- 12 years. Patients that did not perform predischarge ET (Group A, n 77) were retrospectively compared with those who did (Group B, n = 101). In relation to demographic and clinical characteristics; we analysed cardiac events (CE) and death during the first 18 months after discharge in both groups. In group B patients, we studied the relation of ET parameters (duration of exercise, occurrence of exercise-induced ischaemia and arrhythmias, maximum heart rate, blood pressure response, rate pressure product and severity score) to CE and death during the first 18 months after AMI.

RESULTS

The proportion of patients aged 70 years or older was greater in group A (23% vs 3%, P < 0.001). In this group, there was a greater prevalence of recurrent ischaemia (51% vs 29%, P < 0.001) and left ventricular dysfunction (42% vs 25%, P < 0.05). Group A patients were also submitted to less thrombolysis (45% vs 62%, P < 0.05) and to revascularization procedures (25% vs 41%, P < 0.05). In group B patients, the incidence of CE did not differ with respect to duration of ET, rate pressure product or maximum heart rate. Incidence of CE was greater in patients with exercise-induced ischaemia (38% vs 15%, P < 0.05), severity score > 2 (45% vs 18%, P < 0.02) and inadequate rise (< 30 mmHg) in systolic blood pressure (39% vs 13%, P < 0.02). The total incidence of CE and revascularization was also greater in patients with exercise-induced ischaemia (88% vs 49%, P < 0.001), severity score > 2 (95% vs 56%, P < 0.02) and inadequate rise in systolic blood pressure (93% vs 45%, P < 0.001).

CONCLUSIONS

In patients without indication for ET as part of risk stratification after AMI, clinical characteristics were more severe as defined by age greater than 70 years, residual ischaemia and left ventricular dysfunction. Patients that performed ET had smaller risk, except when presenting exercise-induced ischaemia, severity score > 2 and inadequate rise in systolic blood pressure.

[Diastolic dysfunction in patients with chronic kidney failure on a hemodialysis program]

OBJECTIVE

The aim of this study was to analyse different ultrasound parameters for the assessment of isolated left ventricular diastolic dysfunction (LVDD) in patients with chronic renal failure (CRF) on periodic hemodialysis (HD), comparing pulsed wave Doppler with pulsed tissue Doppler.

MATERIALS AND METHODS

Forty-seven patients with CRF on HD (61% were male; mean age was 51.0 +/- 16.5 years, mean HD time--3.7 +/- 3.8 years, 38% had hypertension, 17% had diabetes) were studied by echocardiography (bidimensional, M-Mode, flow pulsed Doppler and tissue Doppler imaging). All patients had symptoms of left heart failure-class II NYHA, were in sinus rhythm and had no symptoms of ischemic heart disease. The presence of abnormal LV regional contractility was the exclusion criteria. According to their mitral inflow profile Doppler characteristics, patients were included in two groups: Group A (E/A > 1; n = 21) and B (E/A < 1; n = 26). We compared: LV dimensions and function, left atrial (LA) dimension. Gaasch index, LV mass index. E and A wave velocities (in flow pulsatile Doppler and tissue Doppler). E/N ratio in tissue Doppler, isovolumetric relaxation time (IVRT) and deceleration time (DT).

RESULTS

There were no significant differences in the prevalence of age > or = 65 years male sex, hypertension or diabetes between group A and B patients, and almost all patients were on hemodialytic treatment for more than one year (81% vs 85%: NS). LV hypertrophy was present in almost all group A and B patients (A--95% vs B--85.5%; NS). Group A, compared with group B, had a difference in the Gaasch index (2.45 +/- 0.3 vs 2.08 +/- 0.4; p < 0.05), E wave velocity in flow pulsatile Doppler and tissue Doppler (cm/sec) (110 +/- 27 vs 62 +/- 20; p < 0.001 and 41 +/- 15 vs 28.5 +/- 16; p < 0.05), E/A ratio in tissue Doppler (1.3 +/- 0.4 vs 0.8 +/- 0.3; p < 0.001). IVRT (msec) (80.7 +/- 15.2 vs 113.5 +/- 28.3; p < 0.001) and DT (msec) (189.7 +/- 24 vs 278.2 +/- 17.9; p < 0.001). According to the E'/A' ratio in tissue Doppler, group A patients were divided in another two groups: E'/A' > 1 (13/21--62%) and < 1 (8/21--38%) and a significantly longer IVRT (75.8 +/- 9.3 vs 100.9 +/- 3.2; p < 0.001) and DT (178 +/- 15 vs 240 +/- 20; p < 0.001) and a greater LA dimension (37.6 +/- 6.9 vs 44.6 +/- 6.9; p < 0.05) were found.

CONCLUSIONS

Pulsed wave Doppler is the most useful non invasive method for assessment of global diastolic dysfunction. In our study, 17% of the patients had E/A < 1 only in the tissue Doppler study. These patients probably had a pseudonormal mitral pattern.

[Role of auxiliary diagnostic tests in the clarification of the etiology of syncope: experience at an arrhythmia center]

Syncope is a syndrome caused by a reversible reduction of blood to the brain. Three hemodynamic abnormalities can cause syncope: an acute decrease in cardiac output, an acute increase in cerebrovascular resistance and a fall in systemic blood pressure due to ineffective control of peripheral vascular resistance. We made a retrospective study of 121 patients with syncope history, 67 males, and 57 females, with mean age 48 +/- 14 years, and at least six months of clinical follow-up. Twelve patients had valvular disease, two patients had hypertrophic cardiomyopathy, eight patients had dilated cardiomyopathy, 14 patients had ischemic disease, three patients had congenital disease; 82 patients did not have cardiac disease. Syncope etiology was arrhythmic in 69 patients: 47 patients had tachyarrhythmia (supraventricular--in 27 patients and ventricular in 20 patients) and 15 patients had bradyarrhythmia (seven patients had sinus node disease and eight patients had atrioventricular block). Non arrhythmic etiology of syncope was identified in 29 patients (neurologic disease--ten patients, metabolic disease--one patient and iatrogenic--two patients; vasodepressor syncope--14 patients, and hypertrophic cardiomyopathy--two patients). It was not possible to determine the syncope etiology in 30 patients. The assessment of patients who present syncope depends on establishing the basis for the symptoms. The initial step is differentiating patients with normal cardiovascular systems from those with heart disease. In the former, tilt-table testing proved to be the most productive from a diagnostic perspective; in the latter group, electrophysiologic evaluation was the most elucidative from a diagnostic perspective. The ultimate goal is to obtain a sufficiently strong correlation between syncopal symptoms and detected abnormalities to permit an accurate assessment of prognosis and to develop an effective treatment plan.

CONCLUSIONS

It is very important to establish the etiology of syncope for optimal management of patients and it is therefore possible to control the symptoms in the majority of them. The patients who present syncope require a complete history and a physical examination for an appropriate workup to be initiated. Tilt-table testing was the most accurate for the diagnosis of vasodepressor syncope while electrophysiologic testing provides an accurate method for assessing the etiology of tachyarrhythmic syncope.

[Value of "cardiac event recorders" in the assessment of sporadic cardiac symptoms]

OBJECTIVES

To determine the value of the Cardiac Event Recorder (CER) in the diagnosis and treatment orientation of bradydysrhythmias, tachydysrhythmias and ischaemic events, based on our experience at the Santa Cruz Hospital.

METHODS

We retrospectively analysed 100 consecutive patients tested with a CER between January 1990 and December 1996 (mean follow-up, 272 +/- 202 days); the mean age of the patients (66 women and 34 men) was 45 +/- 18 years (range: 7 to 83); structural cardiac disease was present in 34% of the patients. CER was indicated for the investigation of symptoms suggestive of bradydysrhythmias (pre-syncope and/or syncope)--Group B--in 24 patients, tachydysrhythmias (palpitations and/or tachycardia sensation)--Group T--in 72 patients and ischaemic events--Group I--in the remaining four patients. We compared these groups with respect to demographic characteristics, prevalence of structural cardiac disease and efficacy of the test in the investigation of symptoms; periodicity of symptoms and duration of CER testing were analysed. In patients that experienced typical symptoms during the test, we analysed the electrocardiogram recorded at the time of the event and we investigated whether abnormal ECG findings influenced the therapeutic approach and whether this led to better symptomatic outcome.

RESULTS

Patients in groups B and T were mainly women (54 percent vs 74 percent, NS). Group B patients were older than group T patients (mean age, 56.4 +/- 17.8 vs 40.0 +/- 16.0 yrs, P < 0.001). In group B, structural cardiac disease was less prevalent (37.5% vs 78.0%, P < 0.001) and symptom periodicity was greater (weekly: 12.5% vs 78.0%, monthly: 87.5% vs 15.2%, P < 0.001) than in group T. Duration of CER testing and number of events recorded were similar in the two groups. In both, CER testing was an important aid for therapeutic approach. Twenty two patients (eight B, 13 T and one I) had no typical symptomatic episodes during the CER test; in the remaining 78 patients (16 B, 59 T and three I), an electrocardiogram recording during such episodes was available for analysis. The ECG was abnormal in 44 of these patients, 12 (75%) being of group B and 32 (54%) of group T. Symptom periodicity was a few weeks in 65% of all patients (6 B, 57 T and two I). Duration of CER testing was < or = two weeks in 91 percent of the patients (22 B, 65 T and four I). CER testing guided the therapeutic approach in 78% of all patients. Changes of treatment strategy were more frequent in patients with CER documented typical symptomatic episodes than in those without (46% vs 9%, P < 0.02). When changes of treatment occurred, symptomatic outcome was better (97% vs 55%, P < 0.001).

CONCLUSIONS

The CER is an important guide for the diagnostic and therapeutic approach for patients with intermittent arrhythmia suggesting, symptoms (78% of patients). A recording of normal ECG during typical symptoms reassures the patient and excludes potentially toxic treatments. Our selection of patients for CER testing seemed adequate since most typical symptomatic events occurred during the first two weeks of the test; longer duration of CER testing seems unnecessary.

[Hemangioma of the right ventricle]

A 36-year-old male with unspecific symptoms and normal physical examination had right cardiac enlargement on chest X-ray. Two-dimensional echocardiographic and thoracic computed tomography demonstrated an intracardiac mass. The tumor was surgically resected and the pathological diagnosis was mixed-type epicardial hemangioma. We discuss this case and review the literature.

[Catheter ablation with radiofrequency energy in 100 patients with Wolff-Parkinson-White syndrome]

OBJECTIVE

The aim of this paper was to evaluate our results of radiofrequency catheter ablation (RFCA) of accessory pathways in patients with WPW syndrome.

STUDY PATIENTS

We studied 100 consecutive patients with WPW syndrome, 52 men and 48 women, mean age 37 +/- 15 years who underwent RFCA. All patients were symptomatic, with documented episodes of supraventricular tachycardia and 9% of patients had underlying cardiac disease.

METHODS

The RFCA was performed without antiarrhythmic drugs in the same session of the electrophysiologic diagnosis. The location of the accessory pathway site was obtained by catheter mapping, based on the premature and/or the presence of Kent potentials. According to the location of the accessory pathway, the ablation catheter was introduced either by the femoral vein or artery with mapping of the tricuspid or mitral ring. In the first cases performed energy application was manually controlled and thereafter was temperature guided with an upper temperature limit of 70 degrees C. We considered primary success criteria the disappearance of the delta wave in the surface ECG and the absence of ventricular preexcitation under atrial pacing and after adenosine injection. Clinical success was defined as the absence of clinical recurrence of tachycardia during the follow-up period.

RESULTS

The primary success rate achieved was 88%; 91% in the left free wall pathways, 100% in the right free wall and 85% in the septal pathways (antero-septal-83%; right postero-septal-76.5%; left postero-septal-92%). A second ablation procedure was performed in seven of the twelve patients with primary unsuccess obtaining a final success rate of 93% (left free wall-94.5%; septal pathways-91.6%). After a mean follow-up period of 8 +/- 7 months clinical recurrence occurred in 9% (eight patients), five of which are under anti-arrhythmic therapy (62.5%). Clinical success rate at the end of the follow-up period was 88%.

CONCLUSIONS

In our experience RFCA has shown to be safe and with a high success rate in patients with symptomatic pre-excitation. In this group of patients it was an effective therapy.

[Acute myocardial infarct in a young cocaine user]

In patients less than 40 years of age, acute myocardial infarction (AMI) has special clinical and pathophysiologic characteristics. Its prevalence varies between 5 and 10%. In such patients, AMI associated with chronic cocaine abuse has a non-negligible prevalence of 6%. The purpose of this report is to describe the case of a 24-year old male patient with smoking habits and chronic abuse of cocaine and hallucinogenic drugs. This patient developed clinical, enzymatic and electrocardiographic criteria of anterior AMI, two hours after the ingestion of an LSD-like hallucinogenic drug. The coronary angiography revealed a critical stenosis of the medium segment of the left anterior descendent artery, and a pre-stenotic aneurysmatic dilatation. In order to determine the etiology of the aneurysm, various laboratory and histologic tests were performed. The results of these were normal. We review the pathophysiology, clinical manifestations and prognosis of cocaine-associated AMI.

[Experience with dl-sotalol in the treatment of supraventricular arrhythmia]

OBJECTIVES

To review the results of our experience with oral dl-sotalol for preventive treatment of supraventricular tachyarrhythmias (atrial fibrillation and paroxysmal supraventricular tachycardia).

POPULATION

51 patients, 28 female and 23 male, mean age 46.2 +/- 14.4 years, from outpatient arrhythmology clinics of our institution, with recurrent supraventricular tachyarrhythmias (atrial fibrillation in 24 patients and paroxysmal supraventricular tachycardia in 27). All the patients, but one, had normal left ventricular function. Dl-sotalol was first choice medication in only three patients. Previously 2 +/- 1.3 antiarrhythmic drugs had been used.

METHODS

Retrospective evaluation of therapeutic response (number of clinical recurrences according to a semi-quantitative scale) and secondary effects of dl-sotalol during a minimum follow-up of 18 months. The mean daily dose was 205 +/- 90 mg (80 to 400 mg).

RESULTS

In 37% of the patients there were no clinical recurrences of arrhythmia during follow-up. In 37% of the patients there was a significant reduction in recurrences. In 26% there was no change in the number of recurrences. There were no significant differences in response between patients with atrial fibrillation and those with paroxysmal supraventricular tachycardia. Secondary effects occurred in 16% of the patients: symptomatic bradycardia, asthma or sexual dysfunction. No patient had heart failure, torsades de pointes, syncope or death.

CONCLUSIONS

From our experience, DL-sotalol seems to be a good therapeutic alternative for the preventive treatment of supraventricular tachyarrhythmias, with a low risk in patients with good ventricular function.